GI: Anti-emetics Flashcards
Common causes of emesis
- Infection
- Meds
- Pregnancy
- Dysmotility
- Motion sickness
Areas of body that communicate to cause emesis
- CNS
- Vestibular system
- Chemoreceptor Trigger zone
- GI Tract & Heart
- Vomiting center

targeted in drug therapy
CNS: role in emesis
Anticipatory N/V, e.g., in cancer pts. Triggering memory
Cortex, thalamus, hypothalamus, meninges

Vestibular system: role in emesis
Motion sickness
H1 and M1 receptors- M1 -muscarinic

Chemoreceptor Trigger Zone: role in emesis
Next to VC
Before BBB, so direct exposure to blood – anything toxic goes to this area, VC –> emesis
Chemoreceptors, D2, NK1, 5-HT3 receptors

GI Tract & Heart: role in emesis
Mechanoreceptors, chemoreceptors, 5HT3 receptors

Vomiting Center: role in emesis
In medulla oblongata
Mainly responsible for coordinating – all other areas communicate to VC
H1, M1, NK1, and 5-HT3 receptors
Types of anti-emetics
5-HT3 receptor antagonists
D2 Receptor Antagonists
Antihistamines & Antimuscarinics
5-HT3 receptor antagonists: where are 5HT3 receptors involved in emesis located?
CTZ, GI Tract & heart, VC
5-HT3 receptor antagonists: indications
- Prevention of chemo/radiation induced N/V
- Post-op N/V (PONV)
- Severe refractory hyperemesis gravidum
- Cyclic vomiting syndrome (pedi)
- Viral gastroenteritis (pedi)
5-HT3 receptor antagonists: MOA
Block central and peripheral 5-HT3 receptors
5-HT3 receptor antagonists: absorption
well=absorbed from GI tract
5-HT3 receptor antagonists: 1/2 life
½ life: 4-9h (except palonosetron = 40h)
5-HT3 receptor antagonists: Metabolism
extensive hepatic via CYP2D6 & CYP3A4
5-HT3 receptor antagonists: ADRs
HA, dizziness, constipation, diarrhea
Caution: QTc interval prolongation
5-HT3 receptor antagonists: Agents
- Ondansetron (Zofran)
- Granisetron (Kytril)
- Dolasetron (Anzemet)
- Palonosetron (Aloxi)
Ondansetron (Zofran): formulation and indication
Tablet, ODT, solution: CINV, once or twice; PONV, once
Injection: CINV & PONV, once
5HT3 Antagonist
Granisetron (Kytril) : formulation and indication
Tablet, solution: CINV once
Injection: CINV & PONV once
Transdermal patch: CINV 24h before chemo
(5HT3 antagonist)
Dolasetron (Anzemet): formulation and indication
Tablet, injection: CINV & PONV once
(5HT3 antagonist)
Palonosetron (Aloxi): formulation and indication
Injection: CINV & PONV once
(5HT3 antagonist)
Recommended Tx: Viral Gastroenteritis
Pedi pts: ondansetron effective in 1) facilitating ORT, 2) decreasing need for IVF and immediate hospitalization risk
Recommended Tx: General N/V
ED studies find ondansetron equivalent to metoclopramide and prochlorperazine in reducing N/V
D2 Receptor Antagonists: agents
- Phenothiazines
- Butyrophenones
- Substituted Benzamides
D2 Receptor Antagonists: Indications
- Most common “general purpose” anti-emetic
- Motion sickness
- Low risk emesis chemotherapy
D2 Receptor Antagonists: MOA
Block dopamine receptors in the CTZ
Sedative effects d/t blockade of histamine receptors
D2 Receptor Antagonists: absorption
well absorbed from GI track, onset 20-30min
D2 Receptor Antagonists: metabolism
hepatic via CYP enzymes, significant 1st pass metabolism
D2 Receptor Antagonists: ADRs
- EPS (dystonia, restlessness)
- Drug induced Parkinson’s
- Drowsiness (phenothiazines, butyrophenones)
- QTc prolongation (phenothiazines, butyrophenones)
Phenothiazine: agents
Prochlorperazine (Compazine), Promethazine (Phenergan)
(D2 receptor antagonists)
Prochlorperazine (Compazine): dosing & formulations
- Tablet: 3-4x daily
- Suppository: BID
- Injection: Q 3-4h prn
(D2RA, phenothiazine)
Phenothiazines: MOA
Same as other D2RAs + Phenothiazines also block muscarinic receptors at VC
(D2RA)
Promethazine (Phenergan): formulations and dosing
- Tablet, solution, suppository, injection
- Q4-6h prn
(D2RA, phenothiazine)
Butyrophenones: Agents
Droperidol
(D2RA)
Droperidol: formulation and dosing
Injection: PONV once
(D2RA, Butyrophenone)
Substituted Benzamides: agents
Metoclopramide (Reglan)
(D2RA)
Metoclopramide (Reglan): dosing and formulations
- Tablet, solution, injection
- Q6h prn
(D2RA, Substituted Benzamide)
Antihistamines & Antimuscarinic: Indication
Motion sickness
Antihistamines & Antimuscarinic: MOA
Block H1 receptors mainly in vestibular system
Anticholinergic effects d/t systemic muscarinic blockade
Antihistamines & Antimuscarinic: ADRs
Drowsiness, confusion, blurred vision, dry mouth, urinary retention, tachycardia
Antihistamines: Agents
Diphenhydramine (Benadryl), Dramamine, Meclizine
Diphenhydramine (Benadryl: formulations and dosing
- Tablet, solution, injection
Q6-8h prn
(antihistamine, antiemetic)
Dramamine: formulation and dosing
Tablet, injection
Q4-6h prn
(antihistamine, antiemetic)
Meclizine: formulations and dosing
Tablet: 1hr before travel
(antihistamine, antiemetic)
Antimuscarinics: Agents
Scopolamine (Transderm-Scop)
Scopolamine (Transderm-Scop): formulations and dosing
Patch: 1 q72h
Injection: once SQ
(antimuscarinic, antiemetic)
1st line anti-emetic in pregnancy
Pyridoxine (Vit B-6) 10-25mg 1-4x daily +/- doxylamine 12.5-20mg 1-4x daily
Now available: Doxylamine succinate/pyridoxine hydrochloride delayed release tabs 10 mg/10mg (Diclegis)
2nd line/additional antiemetic agents in pregnancy
- Diphenhydramine
- Dimenhydrinate
- Meclizine
- ondansetron
- metoclopramide, promethazine, prochlorperazine